https://www.selleckchem.com/products/at13387.html
ions, 27 (54%) having treatment interruptions and no cabozantinib-related deaths observed. Interpretation EORTC 1317 met its primary end-point, with 24/41 patients being progression-free at week 12 of treatment. The objective response was 14% with an encouraging disease control rate of 82%. Results of this trial confirm preclinical findings and warrant further exploration of cabozantinib in GIST. Clinical trial numbers EORTC 1317, NCT02216578, EudraCT 2014-000501-13.Foot pain is a frequent cause of lameness in horses and can involve mul
Curtir
Comentario
Compartilhar
